Eosinophilic asthma is the most common inflammatory phenotype accounting for over 25% of the total severe asthma population and is characterized by an abnormal production of cytokines from T helper type 2 (Th2) lymphocytes and type 2 innate lymphoid cells (ILC-2s), such as IL4, IL-5, or IL-13, and a persistent increase and activation of eosinophils in blood and airways despite receiving treatment with highdoses of corticosteroids [1, 2]. Blood and sputum eosinophilia are associated with more severe disease, worse control, and worse prognosis [3]. The most direct way to diagnose severe eosinophilic asthma is the diagnosis of severe asthma, to have ≥2 exacerbations per year, dependence on oral corticosteroids to achieve asthma control, and to demonstrate the persistent increase of eosinophils in blood and airways [2]. More than 65% of respondents always request a blood eosinophil count during the first visit, ranging from 75.52% of pulmonologists to 55.1% of allergists. This difference between specialties is probably due to the importance that each specialist gives to peripheral eosinophilia. For example, allergists are likely to attribute a more etiological role to it. It is therefore necessary to define the role of peripheral eosinophilia in asthma, even in non-severe asthma.

